Search in:   Search
spacer

Sweden Pharmaceuticals & Healthcare Report Q3 2013

Published by Business Monitor International on May 21, 2013 , 98 pages
PDF - Download Now with 3 Quarterly Updates format - Delivered by download


Description
BMI View: While we expect that the Swedish pharmaceutical market will decline in coming years, under pressure from generic medicines, patent expirations and a general climate of cost containment, we remain optimistic about the country's long-term attractiveness. This view covers both consumption (which is supported by well-developed public financing and healthcare systems) and research and development (R&D) initiatives in the country, with global pharmaceutical major AstraZeneca recently confirming its commitment to local R&D activities.



REPORT TOOLSarrow
Share This Report
Request More Information
Printable Brochure
ORDERINGarrow
Ordering reports couldn't be easier. Select the license for your needs, click Order Now, and complete our streamlined checkout process. We accept major credit cards, wire/bank transfers, and checks.

MC, Visa, AMEX, Diners, Discovery, JCB

PUBLISHERarrow
Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.\n\nBMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including Daily Alerts, monthly regional Insights, and in-depth quarterly Country Forecast Reports.
Publisher Details


Privacy Policy | Terms of Use | Sitemap

Copyright © 2012 Fast Market Research, Inc.